en
Scientific article
English

Bevacizumab Plus Pemetrexed Versus Pemetrexed Alone as Maintenance Therapy for Patients With Advanced Nonsquamous Non-Small-cell Lung Cancer: Update From the Swiss Group for Clinical Cancer Research (SAKK) 19/09 Trial

Published inClinical lung cancer, vol. 18, no. 3, p. 303-309
Publication date2017
Abstract

Pemetrexed and bevacizumab as single agents have been approved for maintenance therapy after platinum-based induction in patients with advanced nonsquamous non-small-cell lung cancer. It is currently unknown whether bevacizumab plus pemetrexed is superior to pemetrexed alone.

Keywords
  • Bevacizumab
  • Chemotherapy
  • Lung cancer
  • Maintenance therapy
  • Pemetrexed
Citation (ISO format)
GAUTSCHI, Oliver et al. Bevacizumab Plus Pemetrexed Versus Pemetrexed Alone as Maintenance Therapy for Patients With Advanced Nonsquamous Non-Small-cell Lung Cancer: Update From the Swiss Group for Clinical Cancer Research (SAKK) 19/09 Trial. In: Clinical lung cancer, 2017, vol. 18, n° 3, p. 303–309. doi: 10.1016/j.cllc.2016.11.007
Main files (1)
Article (Accepted version)
accessLevelRestricted
Identifiers
ISSN of the journal1525-7304
448views
1downloads

Technical informations

Creation03/07/2017 3:20:00 PM
First validation03/07/2017 3:20:00 PM
Update time03/15/2023 1:37:16 AM
Status update03/15/2023 1:37:15 AM
Last indexation01/16/2024 11:49:15 PM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack